Bristol-myers Squibb Compnay

Bristol Meyers Squibb Company

Donald R Gustavson

Kin S Lam

Grace A Hesler

Ronald L Berry

Koji Tomita

Daniel R Schroeder

James A Matson

Wenying Li

John E Leet

Daniel M Brown

Thomas T Dabrah

Kimberly Brown

Laura Turner

Helen A Ax

Novel thiazolyl peptide antibiotic compounds, including nocathiacin I, II and III, are disclosed. Also, novel microorganism ATCC-202099 is disclosed.

Nocathiacin antibiotics

The present invention relates to novel antitumor depsipeptides produced by Micromonospora strain 39500, ATCC 55011, and having the structural formula ##STR1## wherein R.sub.1 is 2-methylpropanoyl, and R.sub.2 is 2-methylppropanoyl, propanoyl or acetyl; or R.sub.1 is 3-methylbutanoyl, and R.sub.2 is 2-methylpropanoyl or 3-methylbutanoyl; or R.sub.1 is propanoyl, and R.sub.2 is acetyl or propanoyl.

Antitumor antibiotics

An antibiotic designated BMY-42448 is produced by fermentation of Micromonospora narashinoensis strain C39217-R109-7 (ATCC-53791). BMY-42448 exhibits both in vitro and in vivo antitumor activity.

Antitumor antibiotic BMY-42448

A new antibiotic designated BMY-42448 is produced by fermentation of Micromonospora narashinoensis strain C39217-R109-7 (ATCC-53791). BMY-42448 exhibits both in vitro and in vivo antitumor activity.

Growing community of inventors

Torrington, CT, United States of America

Donald R Gustavson